[ad_1]
A Washington County confirmed on Tuesday that a woman died from complications from blood clotting after receiving the single-dose COVID-19 vaccine from Johnson & Johnson. She is believed to be the fourth person to die from such a complication.
King County said a resident in her 30s died from a “very rare” complication. The unnamed resident received her J&J shot on August 26.
“Its cause of death was determined to be thrombosis with thrombocytopenia syndrome (TTS), a disease that has been identified as a rare but potentially serious adverse event in people who received the J&J vaccine,” the county said in a report. communicated.
When contacted for comment on The Hill, Johnson & Johnson said in a statement:
“The safety and well-being of everyone who receives a Johnson & Johnson product remains our top priority. Any adverse event reports regarding people receiving the Johnson & Johnson single injection COVID-19 vaccine, as well as our own assessment of the report, are shared with the United States Food and Drug Administration (FDA), the Agency. European Medicines Agency, the World Health Organization (WHO) and other relevant health authorities where our vaccine is authorized.
The company added that it was supporting awareness of the signs of the rare side effect to “ensure they can be quickly identified and treated effectively.”
Earlier this year, administration of the J&J vaccine was briefly halted while U.S. health officials examined the rare complication of blood clotting. Such complications from the J&J vaccine appear to be more common in women than in men.
Officials ultimately determined that the benefits of the J&J vaccine outweighed the risks, and states resumed administration of the vaccine in April.
King County noted that women aged 18 to 49 were at a higher risk of complications than women over 50. However, regardless of their age, the county added that the benefits always outweighed the risks of not getting the shot.
J&J scientists also said in April that there was “insufficient” evidence of a “causal relationship” between the company’s COVID-19 vaccine and the reported complications.
According to the Centers for Disease Control and Prevention, nearly 15 million doses of J&J’s coronavirus vaccine have been administered in the United States so far.
A similar complication has been observed with the AstraZeneca COVID-19 vaccine, with many European countries choosing to stop administering it. Other countries such as the UK have decided to limit the AstraZeneca vaccine to people over 30, as younger people would be more susceptible to complications.
AstraZeneca vaccine has not been approved for use in the United States
Updated at 4:11 p.m.
[ad_2]
Source link